Stock ANNX ANNEXIN PHARMACEUTICALS AB
Add to a list
To use this feature you must be a member
Log inSign up

Company Annexin Pharmaceuticals AB

Equities

ANNX

SE0009664154

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 10:54:42 2024-04-26 am EDT 		5-day change 1st Jan Change
0.297 SEK +2.41% Intraday chart for Annexin Pharmaceuticals AB +10.00% +14.23%
Apr. 12 Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Feb. 09 Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI

Business Summary

Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Company’s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Number of employees: 4

Managers

Managers TitleAgeSince
Anna Frostegård FOU
 Founder 51 13-12-31
Nils Anders Haegerstrand CEO
 Chief Executive Officer 63 17-12-31
Susanne Andersson DFI
 Director of Finance/CFO 53 23-04-10
Susan Suchdev COO
 Chief Operating Officer 52 -
Alain Thibault PRN
 Corporate Officer/Principal - 23-01-17

Members of the board

Members of the board TitleAgeSince
Uli Alf Hacksell CHM
 Chairman 74 20-12-31
Mårten Österlund BRD
 Director/Board Member 67 20-12-31
Nils Anders Haegerstrand CEO
 Chief Executive Officer 63 17-12-31
Carl-Fredrik Lindner BRD
 Director/Board Member 48 16-12-31
Erik Johan Frostegård BRD
 Director/Board Member 65 15-12-31
Gisela Marie Sitbon BRD
 Director/Board Member 66 16-12-31
Curt Mikael von Euler-Chelpin BRD
 Director/Board Member 71 -
Anthon Jahreskog BRD
 Director/Board Member 44 21-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 346,583,688 75,900,956 ( 21.90 %) 0 21.90 %

Company contact information

Annexin Pharmaceuticals AB

Kammakargatan 48

111 60, Stockholm

+

http://www.annexinpharma.com
address Annexin Pharmaceuticals AB(ANNX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ANNEXIN PHARMACEUTICALS AB Stock Annexin Pharmaceuticals AB
+14.23% 9.39M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ANNX Stock
  4. Company Annexin Pharmaceuticals AB